編者按：由國際胸腺腫瘤協(xié)會(huì )（International Thymic Malignancy Interesting Group， ITMIG）舉辦的第8屆年會(huì )于2017年9月21日-23日在意大利都靈Lingotto會(huì )議中心圓滿(mǎn)召開(kāi)。來(lái)自意大利Fondazione IRCCS Istituto Nazionale Tumori胸外科的Ugo Pastorino教授就“Extended Surgical Resection for Stage III Thymic Tumors”一題作了精彩的演講。會(huì )后，我們十分榮幸地采訪(fǎng)到了Pastorino教授。

 

　　Ugo Pastorino， MD

 

　　Ugo Pastorino graduated in Medicine in 1979 at the University of Milan and specialized in Emergency Surgery， Oncology and Thoracic Surgery. In 1991 launched the International Registry of Lung Metastases. Appointed as consultant thoracic surgeon at the Royal Brompton Hospital of London in 1994， is Director of Thoracic Surgery at the Istituto Nazionale Tumori of Milan from 2003， and Scientific Director in 2014/2015. From 2001 to 2014 was Associate Editor of the Journal of the National Cancer Institute， and from 2014 is Editor in Chief of Tumori Journal. Author of 332 papers with Impact Factor (H-index： 48)， has been principal investigator of a number of randomised trials on chemoprevention and adjuvant chemotherapy， and is presently responsible of three prospective trials on lung cancer screening with LDCT and circulating biomarkers.

 

　　在訪(fǎng)談中，Pastorino教授向我們介紹了在胸腺瘤手術(shù)中，開(kāi)胸手術(shù)是最為常見(jiàn)的手術(shù)方式。對于III期胸腺腫瘤在擴大切除手術(shù)前，醫生們往往是需要考慮進(jìn)行新輔助治療的。作為一名肺外科專(zhuān)家，Pastorino教授致力于研究多原發(fā)肺小結節治療已有二十余年，他與我們分享了他們團隊在對非實(shí)性病變或部分實(shí)性的病變實(shí)施將近10年的主動(dòng)監測的研究成果。他提出，大部分的該類(lèi)型病變不會(huì )進(jìn)一步發(fā)展，但有時(shí)候實(shí)性病變部分會(huì )增長(cháng)，因此醫生要控制好病變的情況。而隨著(zhù)CT檢查的進(jìn)步，出現過(guò)度治療的情況也減少了。在采訪(fǎng)的最后，Pastorino教授針對肺癌患者在液體活檢技術(shù)在術(shù)前及術(shù)后的評估也提出自己寶貴的看法。

 

 

　　1. The surgical outcome of patients with early stage thymoma is generally pleasant. In you center， which approach do you apply more for those patients？ Minimally invasive surgery or open surgery？

 

　　2. Prior to extended resection surgery for patients with stage Ⅲ thymoma， is it necessary to consider neoadjuvant therapy？

 

　　3. You have contributed significantly to field of pulmonary surgery. From your experiences， how to choose strategies for the treatment of multiple primary GGO/GGN？ (ground-glass opacity/ ground-glass nodules)

 

　　4. Screening of lung cancer has generally lowered its mortality. In your center， what’s the proportion of postoperative benign pathologic results in patients with suspicion of early stage NSCLC patients？ How to control and reduce potential excessive treatment？

 

　　5. How do you see the estimation of liquid biopsy in pre-operation and post-operation for lung cancer patients？